Stoke Therapeutics, Inc. (STOK)
After hours:
| Previous close | 3.5800 |
| Open | 3.5700 |
| Bid | 3.3800 x 800 |
| Ask | 3.7600 x 1200 |
| Day's range | 3.3700 - 3.5900 |
| 52-week range | 3.3700 - 16.4800 |
| Volume | |
| Avg. volume | 401,989 |
| Market cap | 157.683M |
| Beta (5Y monthly) | 0.34 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.3100 |
| Earnings date | 13 Nov 2023 - 17 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 20.75 |
Business WireStoke Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
BEDFORD, Mass., September 21, 2023--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will participate in a panel presentation at the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, 2023, at 9:55 a.m. ET.
Business WireStoke Therapeutics Appoints Ian Smith to its Board of Directors
BEDFORD, Mass., September 20, 2023--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Ian Smith to its Board of Directors effective September 19.
Business WireStoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet Syndrome at the 35th International Epilepsy Congress
DUBLIN, September 05, 2023--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced highlights from presentations related to the ongoing clinical development of STK-001, the first potential new medicine to treat the underlying cause of Dravet syndrome. Four posters from the Company’s work in Dravet syndrome are being presented at the International
